HARP News and Press, Harpoon Therapeutics Inc. From 01/08/24

2024-01-08 02:39:13 ET Merck ( NYSE: MRK ) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics ( NASDAQ: HARP ) for around $700M. Citing people familiar with the matter, Bloomberg News reported on Sunday that Merck ( MRK ) is discu...

2023-12-30 09:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data f...

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At the 12 mg dose, cohorts demonstrated favorable acti...

2023-12-08 16:30:47 ET More on Harpoon Therapeutics Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more For further details see: Harpoon Therapeutics files to sell 25.75...

2023-11-27 13:24:37 ET Gainers: Redhill Biopharma Ltd. ( RDHL ) +198% . Biodexa Pharmaceuticals Plc ( BDRX ) +119% . Direct Digital Holdings ( DRCT ) +34% . Captivision ( CAPT ) +29% . MoneyHero Ltd ( MNY ) +28% . Beachbody C...

2023-11-27 10:50:10 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

2023-11-24 09:46:18 ET More on Health Care Select Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment ...

2023-11-21 09:00:00 ET Summary HPN328 is being advanced in a phase 1/2 study for the treatment of patients with neuroendocrine tumors; Promising interim data was released at ESMO 2023 medical conference. Updated data from the phase 1/2 study, using HPN328 for the treatment of pati...

2023-11-10 10:46:28 ET More on Harpoon Therapeutics Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more Harpoon climbs on data for cancer drug (updated) Seeking Alpha’s Quant Rating on Harpoon Therapeutics Historical earnin...